Like many small biotechnology companies Intercell AG has had to abandon promising projects because they failed in clinical trials. Yet, unlike many other companies Intercell has product revenue. Its vaccine against Japanese encephalitis, Ixiaro/Jespect, had sales of €21.6 million in 2011.
